On July 22, 2025, Ikena Oncology, Inc. announced a special dividend of one contingent value right (CVR) for each outstanding share, applicable to stockholders as of July 24, 2025, in relation to a merger with Inmagene Biopharmaceuticals. This special dividend allows CVR holders to potentially receive net proceeds from certain asset agreements, contingent on specific payments being made after the merger's closing.